(Q39049252)

8 September 2017

title

Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? (English)

1 reference

8 September 2017

1 reference

4

Joseph R Calabrese

1 reference

8 September 2017

Fang Fang

1

1 reference

8 September 2017

Zuowei Wang

series ordinal

2

1 reference

8 September 2017

Renrong Wu

series ordinal

3

1 reference

8 September 2017

Keming Gao

series ordinal

5

1 reference

8 September 2017

publication date

22 December 2016

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

8 September 2017

published in

1 reference

8 September 2017

volume

17

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

407-418

1 reference

Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysis

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Weight gain and metabolic issues of medicines used for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Almost all antipsychotics result in weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Balancing benefits and harms of treatments for acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Risperidone in the treatment of acute mania: double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

Emerging drugs for schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1276284

10.1080/14737175.2016.1276284

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference